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The earliest written record of tuberculosis (TB) in Tasmania comes from Colonel David Collins, who reported in 1804 that a member of his Hobart settlement had consumption ([@B1]). Today, Tasmania is regarded as a low-TB-burden state with an incidence rate of 1.7/100,000 persons compared to 5.7/100,000 nationally in Australia in 2014 ([@B2]). Until recently, Tasmania had been free of multidrug-resistant (MDR) forms of TB; however, in 2016 its first case of MDR-TB was reported.

We have previously characterized the genomes of MDR and extensively drug-resistant (XDR) *Mycobacterium tuberculosis* ([@B3][@B4][@B5]). Here, genomic DNA of the Tasmanian isolate, TASMDR1, was sequenced using an Illumina MiSeq instrument. A total of 2,860,297 paired-end reads were mapped to the publicly available annotated genome of *M. tuberculosis* reference strain H37Rv (GenBank accession number NC_000962.3) ([@B6]) by Burrows-Wheeler alignment ([@B7]). This yielded an average read depth of 65.5-fold, covering 97.8% of the H37Rv genome. Variants relative to the H37Rv reference genome were called using the SAMtools analysis suite, and variant annotation was performed using SnpEff ([@B8], [@B9]). A 4,230,496-bp draft genome assembly of 220 contigs was assembled *de novo* using the SPAdes assembler (v3.7) ([@B10]). Assembled contigs were ordered with respect to the *M. tuberculosis* H37Rv genome using ABACAS ([@B11]).

A total of 1,553 variant sites were identified relative to the H37Rv genome and consisted of 1,408 single-nucleotide variants (SNVs) and 145 insertions/deletions. Of the variants, 881 were nonsynonymous; of these, 784 were SNVs and 97 were insertions/deletions. The genome of TASMDR1 displayed high-confidence single-nucleotide polymorphisms in genes correlating with antimicrobial drug resistance when analyzed using the PhyResSE database ([@B12]). These include high-confidence mutations in the *katG* gene (aGc/aCc, S315T) and *rpoB* gene (gAc/gGc, D435G; tCg/tTg, S450L), which underlie *M. tuberculosis* resistance to isoniazid and rifampin, respectively ([@B13], [@B14]). These data establish the genetic bases of the MDR phenotype exhibited by strain TASMDR1.

Additional mutations were detected in the *embB* gene (Atg/Gtg, M306V) and *pncA* gene (cCg/cTg, P62L) that are associated with resistance to ethambutol and pyrazinamide, respectively ([@B15][@B16][@B18]). Furthermore, an A/C substitution was detected at position 514 of the 16S rRNA gene, *rrs* (MTB000019), and is related to streptomycin resistance ([@B19], [@B20]). The TASMDR1 isolate belongs to the Beijing sublineage of East Asian Lineage 2, as predicted by the PhyResSE and TB Profiler databases ([@B12], [@B21]).

The drug-resistance mutations that were identified in the genome of the TASMDR1 isolate were detected within a significantly shorter turn-around time compared to conventional phenotypic drug-susceptibility testing. Although MDR-TB isolates are currently rare in Tasmania, this study highlights the utility of having a microbial whole-genome sequencing facility available for rapidly determining the resistance profiles of MDR-TB isolates that may present in a low-TB-incidence setting.

Accession number(s). {#s1}
--------------------

This whole-genome shotgun project has been deposited at DDBJ/ENA/GenBank under the accession number [NTFG00000000](https://www.ncbi.nlm.nih.gov/nuccore/NTFG00000000). The version described in this paper is version NTFG01000000.
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